ATOM Coalition sees patent sharing as key to overcoming scarcity of cancer drugs in LLMICs

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.

FTC launches investigation of the roles GPOs, wholesalers play in causing drug shortages

The Federal Trade Commission has launched an investigation into the role of hospital group purchasing organizations and dominant wholesalers in causing decades-long shortages of hundreds of lifesaving drugs.

February 16, 2024

Vol.50 No.07

In Brief

WHO, St. Jude coordinate evacuations for children with cancer from Gaza to Egypt, Jordan

About 12 children with cancer or other blood disorders have been evacuated, with their companions, from the Gaza Strip in the occupied Palestinian territory to Egypt and Jordan so they may continue their treatment safely. Additional children are expected to be evacuated for cancer treatment as part of this initiative.

November 10, 2023

Vol.49 No.42

Clinical

ASCO’s Julie Gralow: “There was clearly a shortage of drug, but there was a bigger problem of maldistribution”

If you’ve been following the saga of drug shortages in this publication, you know how America’s cancer institutions are scrambling to obtain platinum-based drugs for their patients.

September 29, 2023

Vol.49 No.36

By Jacquelyn Cobb

NCI Director's Report

Bertagnolli: Drug shortages, potential NCI budget cuts strain the already-stressed system

NCI continues to face the prospect of flat funding in fiscal year 2024 as a spending bill proposes a 3% cut to NCI’s budget, which threatens to further reduce the institute’s purchasing power, said NCI Director Monica Bertagnolli.

July 28, 2023

Vol.49 No.30

By Matthew Bin Han Ong

Clinical

An oncologist’s nightmare: “As of today, we no longer have any supply of carboplatin.”

A survey conducted by the National Comprehensive Cancer Network found that 93% of its 27 member institutions are experiencing shortages of carboplatin, and 70% lack cisplatin.

June 16, 2023

Vol.49 No.24

By Paul Goldberg

ATOM Coalition sees patent sharing as key to overcoming scarcity of cancer drugs in LLMICs

YOU MAY BE INTERESTED IN

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

FTC launches investigation of the roles GPOs, wholesalers play in causing drug shortages

WHO, St. Jude coordinate evacuations for children with cancer from Gaza to Egypt, Jordan

ASCO’s Julie Gralow: “There was clearly a shortage of drug, but there was a bigger problem of maldistribution”

Bertagnolli: Drug shortages, potential NCI budget cuts strain the already-stressed system

An oncologist’s nightmare: “As of today, we no longer have any supply of carboplatin.”

Renew today!

Subscriber content

Login

ATOM Coalition sees patent sharing as key to overcoming scarcity of cancer drugs in LLMICs

YOU MAY BE INTERESTED IN

Platinum drugs are off the shortage list, but the underlying problem is unsolvedFDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

FTC launches investigation of the roles GPOs, wholesalers play in causing drug shortages

WHO, St. Jude coordinate evacuations for children with cancer from Gaza to Egypt, Jordan

ASCO’s Julie Gralow: “There was clearly a shortage of drug, but there was a bigger problem of maldistribution”

Bertagnolli: Drug shortages, potential NCI budget cuts strain the already-stressed system

An oncologist’s nightmare: “As of today, we no longer have any supply of carboplatin.”

Login

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”